Charles River to provide GMP NGS testing services to Arovella Therapeutics under new collaboration
CRL•CRL•CRL•CRL•Charles River will also run viral safety release testing for clinical batches of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ lymphomas and leukemias.
Charles River entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequencing services for cell bank characterization.
FDA acceptance of NGS viral safety testing supported Arovella’s IND for two cell banks used in the ALA-101 manufacturing process.
